Loading...

Respiri

ASX:RSH
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RSH
ASX
A$51M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Respiri Limited, a health technology company, researches, develops, commercializes, and sells medical devices in Australia and Israel. The last earnings update was 57 days ago. More info.


Add to Portfolio Compare Print
  • Respiri has significant price volatility in the past 3 months.
RSH Share Price and Events
7 Day Returns
1%
ASX:RSH
-1.8%
AU Medical Equipment
0.5%
AU Market
1 Year Returns
-28.1%
ASX:RSH
-2.8%
AU Medical Equipment
4.9%
AU Market
RSH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Respiri (RSH) 1% 29.3% 10.2% -28.1% 177.1% -46.1%
AU Medical Equipment -1.8% -0.2% -1% -2.8% 40.5% 105.5%
AU Market 0.5% 1.9% 8% 4.9% 19.5% 6.3%
1 Year Return vs Industry and Market
  • RSH underperformed the Medical Equipment industry which returned -2.8% over the past year.
  • RSH underperformed the Market in Australia which returned 4.9% over the past year.
Price Volatility
RSH
Industry
5yr Volatility vs Market

Value

 Is Respiri undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Respiri. This is due to cash flow or dividend data being unavailable. The share price is A$0.097.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Respiri's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Respiri's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:RSH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.01
ASX:RSH Share Price ** ASX (2019-04-24) in AUD A$0.1
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 34.61x
Australia Market PE Ratio Median Figure of 544 Publicly-Listed Companies 16.19x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Respiri.

ASX:RSH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:RSH Share Price ÷ EPS (both in AUD)

= 0.1 ÷ -0.01

-8.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Respiri is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • Respiri is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Respiri's expected growth come at a high price?
Raw Data
ASX:RSH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.67x
Australia Market PEG Ratio Median Figure of 359 Publicly-Listed Companies 1.38x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Respiri, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Respiri's assets?
Raw Data
ASX:RSH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.00
ASX:RSH Share Price * ASX (2019-04-24) in AUD A$0.1
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.75x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.68x
ASX:RSH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:RSH Share Price ÷ Book Value per Share (both in AUD)

= 0.1 ÷ 0.00

32.98x

* Primary Listing of Respiri.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Respiri is overvalued based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess Respiri's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Respiri has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Respiri expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Respiri has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.2%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Respiri expected to grow at an attractive rate?
  • Unable to compare Respiri's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Respiri's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Respiri's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:RSH Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:RSH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:RSH Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -4 -6
2018-09-30 1 -3 -4
2018-06-30 1 -2 -3
2018-03-31 1 -2 -2
2017-12-31 2 -2 -1
2017-09-30 1 -2 -2
2017-06-30 1 -3 -3
2017-03-31 1 -3 -3
2016-12-31 1 -3 -3
2016-09-30 1 -3 -4
2016-06-30 1 -2 -4
2016-03-31 0 -3 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Respiri is high growth as no earnings estimate data is available.
  • Unable to determine if Respiri is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:RSH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Respiri Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:RSH Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 0.00
2017-09-30 0.00
2017-06-30 -0.01
2017-03-31 -0.01
2016-12-31 -0.01
2016-09-30 -0.01
2016-06-30 -0.01
2016-03-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Respiri will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Respiri's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Respiri's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Respiri's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Respiri's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Respiri has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Respiri performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Respiri's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Respiri does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Respiri's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Respiri's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Respiri's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Respiri Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:RSH Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.02 -5.53 2.96 3.59
2018-09-30 0.94 -4.37 2.70 2.55
2018-06-30 0.86 -3.21 2.45 1.51
2018-03-31 1.28 -2.32 2.29 1.13
2017-12-31 1.69 -1.44 2.13 0.75
2017-09-30 1.26 -1.98 2.04 0.94
2017-06-30 0.83 -2.52 1.94 1.12
2017-03-31 0.75 -2.89 1.92 1.24
2016-12-31 0.67 -3.26 1.89 1.37
2016-09-30 0.68 -3.64 1.84 1.34
2016-06-30 0.68 -4.01 1.79 1.31
2016-03-31 0.39 -4.52 1.55 1.98
2015-12-31 0.10 -5.03 1.31 2.65
2015-09-30 0.10 -5.25 1.81 2.85
2015-06-30 0.09 -5.46 2.32 3.05
2015-03-31 0.05 -5.85 3.15 2.98
2014-12-31 0.01 -6.23 3.98 2.91
2014-09-30 0.01 -8.27 5.57 3.38
2014-06-30 0.02 -10.31 7.16 3.84
2014-03-31 0.20 -10.06 6.92 3.55
2013-12-31 0.38 -9.81 6.67 3.26
2013-09-30 0.37 -7.70 5.09 2.71
2013-06-30 0.37 -5.58 3.50 2.16
2013-03-31 0.47 -5.43 3.45 1.98
2012-12-31 0.56 -5.29 3.40 1.81
2012-09-30 0.56 -5.44 3.65 1.67
2012-06-30 0.56 -5.59 3.90 1.52

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Respiri has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Respiri has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Respiri improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Respiri's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Respiri has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Respiri's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Respiri's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Respiri is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Respiri has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Respiri's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Respiri has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Respiri Company Filings, last reported 3 months ago.

ASX:RSH Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1.51 0.00 2.99
2018-09-30 1.51 0.00 2.99
2018-06-30 1.65 0.00 2.43
2018-03-31 1.65 0.00 2.43
2017-12-31 1.01 0.00 1.05
2017-09-30 1.01 0.00 1.05
2017-06-30 1.80 0.00 1.59
2017-03-31 1.80 0.00 1.59
2016-12-31 2.39 0.00 2.72
2016-09-30 2.39 0.00 2.72
2016-06-30 4.04 0.00 4.51
2016-03-31 4.04 0.00 4.51
2015-12-31 1.29 0.00 1.43
2015-09-30 1.29 0.00 1.43
2015-06-30 3.90 0.00 3.09
2015-03-31 3.90 0.00 3.09
2014-12-31 6.18 0.00 5.40
2014-09-30 6.18 0.00 5.40
2014-06-30 9.08 0.00 8.21
2014-03-31 9.08 0.00 8.21
2013-12-31 9.39 0.00 10.04
2013-09-30 9.39 0.00 10.04
2013-06-30 1.62 0.00 1.35
2013-03-31 1.62 0.00 1.35
2012-12-31 4.13 0.01 3.80
2012-09-30 4.13 0.01 3.80
2012-06-30 2.11 0.00 1.33
  • Respiri has no debt.
  • Respiri had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Respiri has less than a year of cash runway based on current free cash flow.
  • Respiri has less than a year of cash runway if free cash flow continues to reduce at historical rates of -10.3% each year.
X
Financial health checks
We assess Respiri's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Respiri has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Respiri's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Respiri dividends.
If you bought A$2,000 of Respiri shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Respiri's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Respiri's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:RSH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Respiri has not reported any payouts.
  • Unable to verify if Respiri's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Respiri's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Respiri has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Respiri's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Respiri afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Respiri has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Respiri's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mario Gattino
COMPENSATION A$492,832
TENURE AS CEO 1.3 years
CEO Bio

Mr. Mario Gattino serves as Executive Director of Respiri Limited since December 14, 2017. He has been the Chief Executive Officer at Respiri Limited since December 1, 2017. Mr. Gattino served as Country Chief Executive Officer in Budapest including responsibility for logistics and distribution in central and Eastern Europe. His latest role was Vice President and General Manager (ANZ) for Ikaria Inc., where he turned around its Australia and New Zealand business and was responsible for spearheading an expansion into APAC. Other key roles he has held include Managing Director for Perrigo ANZ, a company that makes a wide range of consumer healthcare products and was the key advisor to an in- vitro diagnostic start-up where he developed its global commercialisation strategy and successfully raised capital. Mr. Gattino has over 25 years' experience in senior leadership positions within the medical industry. He has held senior leadership positions at Pfizer. He has a long successful track record in commercializing drug and device products globally and growing sales in multiple markets including the USA, Europe and Asia. He is an expert in sophisticated stakeholder management, portfolio and business development via M&A and licensing, brand commercialization, business innovation and profit generation. His experience in launching and managing products in several countries, formulating and executing commercialization plans and dealing with local regulators be invaluable to Respiri at this important juncture, he spent 20 years working with Pfizer including serving as the Chief Operating Officer & Regional Business Director responsible for operational issues in ten Northern European countries. He holds an MBA from the University of NSW (AGSM) and a Bachelor of Applied Science (Medical Administration) from La Trobe University.

CEO Compensation
  • Insufficient data for Mario to compare compensation growth.
  • Mario's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Respiri management team in years:

1
Average Tenure
  • The average tenure for the Respiri management team is less than 2 years, this suggests a new team.
Management Team

Mario Gattino

TITLE
CEO & Executive Director
COMPENSATION
A$493K
TENURE
1.3 yrs

Wani Wall

TITLE
Chief Customer Experience & Communications Officer
TENURE
0.8 yrs

Jan Barker

TITLE
Vice-President of Business Development
TENURE
7.3 yrs

Samaneh Sarraf

TITLE
Chief Research Officer

Alastair Beard

TITLE
Company Secretary
TENURE
0.1 yrs

Noam Gavriely

TITLE
Medical & Scientific Advisor
COMPENSATION
A$311K

Simon Godfrey

TITLE
Medical & Scientific Advisor
Board of Directors Tenure

Average tenure of the Respiri board of directors in years:

0.4
Average Tenure
  • The average tenure for the Respiri board of directors is less than 3 years, this suggests a new board.
Board of Directors

Ross James Blair-Holt

TITLE
Non-Executive Chairman
COMPENSATION
A$11K
TENURE
0.3 yrs

Mario Gattino

TITLE
CEO & Executive Director
COMPENSATION
A$493K
TENURE
1.3 yrs

Bruce Thompson

TITLE
Non-Executive Director
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
04. May 18 Buy Mario Gattino Individual 30. Apr 18 03. May 18 320,000 A$0.15 A$46,215
01. May 18 Buy Mario Gattino Individual 27. Apr 18 27. Apr 18 100,000 A$0.14 A$13,500
X
Management checks
We assess Respiri's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Respiri has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Does Respiri Limited (ASX:RSH) Need To Issue More Shares?

Respiri Limited (ASX:RSH) continues its loss-making streak, announcing negative earnings for its latest financial year ending. … Looking at Respiri’s latest financial data, I will gauge when the company may run out of cash and need to raise more money. … View out our latest analysis for Respiri?

Simply Wall St -

All You Need To Know About Respiri Limited's (ASX:RSH) Risks

A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … Based on this beta value, RSH appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … RSH, with its market capitalisation of AUD A$16.90M, is a small-cap stock, which generally have higher beta than similar companies of larger size.

Simply Wall St -

Will Respiri Limited (ASX:RSH) Need To Raise More Money?

With a negative operating cash flow of -$2.91M, RSH is chipping away at its $1.59M cash reserves in order to run its business. … The measure of how fast RSH goes through its cash reserves over time is called the cash burn rate. … The cash burn analysis result indicates a cash constraint for RSH, due to its current level of cash reserves.

Simply Wall St -

Company Info

Description

Respiri Limited, a health technology company, researches, develops, commercializes, and sells medical devices in Australia and Israel. The company produces and sells mobile health applications. Its products include SonoSentry, an over-the-counter wheeze detection device; and Wholter, a device for home ambulatory recording of nocturnal wheeze and cough. The company also offers PulmoTrack, a computerized wheeze detection product designed for hospital/clinical based real-time monitoring of wheeze and cough in the management of acute asthma in the ER and ICU, and for pediatric pulmonary function testing and sleep labs. In addition, it is developing AirSonea, an app featuring asthma management diary, medication usage and reminders, and symptoms and triggers for asthma sufferers. The company was formerly known as iSonea Limited and changed its name to Respiri Limited in December 2015. Respiri Limited is based in Melbourne, Australia.

Details
Name: Respiri Limited
RSH
Exchange: ASX
Founded:
A$51,010,660
525,883,098
Website: http://respiri.co
Address: Respiri Limited
101 Collins Street,
Level 27,
Melbourne,
Victoria, 3000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX RSH Ordinary Shares Australian Securities Exchange AU AUD 15. Nov 2006
OTCPK KMLX.F Ordinary Shares Pink Sheets LLC US USD 15. Nov 2006
CHIA RSH Ordinary Shares Chi-X Australia AU AUD 15. Nov 2006
Number of employees
Current staff
Staff numbers
0
Respiri employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 10:32
End of day share price update: 2019/04/24 00:00
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.